Nanosonics Director Adjusts Equity Holdings
I'm PortAI, I can summarize articles.
Nanosonics Limited (AU:NAN) announced a change in director Michael Kavanagh's equity holdings, acquiring 109,685 ordinary shares through the Omnibus Equity Plan. This adjustment aims to align management interests with shareholder value, potentially influencing investor confidence. The latest analyst rating for AU:NAN is a Buy with a price target of A$4.50. Nanosonics specializes in medical technology, particularly infection prevention solutions, and has a current market cap of A$1.25B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments